Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Aug 23, 2021 8:01am

278 Views

Post# 33747413

Peer Based Proxy Valuation.. $10 + CAD per share

EV = M Cap + debt - Cash =$25 m cad

Ebitda = $4.1 m US x 4 X 1.25 = $20 million cad

Ev to Ebitda valuation Multiple

14.40 for Biotech
14.32 for Pharm

Average is 14.36 times

So we have fair value EV of 14.36 X $20 m cad = $285 million CAD

To this we add the $20 m CAD in Cash and fair value Market cap = $305 m CAD

And $305 m CAD divided by 27 m shares $11.25 per share

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec